Ansa Biotechnologies
Private Company
Total funding raised: $80M
Overview
Ansa Biotechnologies, founded in 2018, is pioneering a novel enzymatic approach to DNA synthesis. Its core technology utilizes TdT-dNTP conjugates to build DNA strands base-by-base with high fidelity, enabling the production of long (up to 50 kb) and complex sequences that are difficult for competitors. Operating as a platform and service provider, Ansa is positioned to disrupt the synthetic DNA supply chain by offering faster, more reliable, and cost-effective products for the rapidly growing synthetic biology market. The company is privately held and appears to be in an early revenue stage, serving research and development customers.
Technology Platform
Proprietary enzymatic DNA synthesis using TdT-dNTP conjugates for direct, no-assembly synthesis of long and complex DNA sequences.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Ansa competes in the DNA synthesis market against dominant chemical synthesis providers like Twist Bioscience and Integrated DNA Technologies (IDT). Its primary competitors are other enzymatic synthesis startups such as DNA Script, Molecular Assemblies, and Elegen, each with different technical approaches. Competition is based on synthesis length, speed, accuracy, cost, and ease of integration into workflows.